Stocks Overview

LAST PRICE
42.5200
TODAY'S CHANGE (%)
Trending Down-0.0300 (-0.0705%)

Bid / Lots
42.2000/ 1
Ask / Lots
42.4100/ 3
Open / Previous Close
42.5300 / 42.5500
Day Range
Low 42.4000
High 42.6600
52 Week Range
Low 19.5900
High 43.5898
Volume
676,474
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Friday's close: 42.55
Time	Volume	CERE
09:32 ET	4241	42.66
09:34 ET	200	42.61
09:36 ET	1000	42.58
09:38 ET	4011	42.58
09:39 ET	3006	42.55
09:41 ET	300	42.54
09:43 ET	3420	42.61
09:48 ET	200	42.58
09:50 ET	1975	42.57
09:52 ET	1100	42.59
09:54 ET	200	42.58
09:56 ET	21516	42.55
09:57 ET	200	42.555
09:59 ET	5198	42.505
10:01 ET	1172	42.52
10:03 ET	200	42.5
10:06 ET	2470	42.525
10:08 ET	1465	42.535
10:10 ET	300	42.525
10:12 ET	1500	42.535
10:14 ET	4147	42.535
10:15 ET	1683	42.53
10:17 ET	1144	42.525
10:19 ET	800	42.53
10:21 ET	1600	42.53
10:24 ET	2564	42.505
10:26 ET	700	42.5
10:28 ET	300	42.5
10:30 ET	1039	42.5
10:32 ET	2400	42.5
10:33 ET	600	42.505
10:35 ET	885	42.5
10:37 ET	5979	42.5
10:39 ET	3400	42.5
10:42 ET	46694	42.475
10:44 ET	6136	42.45
10:46 ET	8391	42.4
10:48 ET	5792	42.41
10:50 ET	1318	42.415
10:51 ET	5311	42.425
10:53 ET	5300	42.425
10:55 ET	336	42.425
10:57 ET	2241	42.425
11:00 ET	900	42.425
11:02 ET	500	42.425
11:04 ET	2248	42.44
11:06 ET	500	42.43
11:08 ET	500	42.425
11:09 ET	400	42.425
11:11 ET	300	42.425
11:13 ET	3570	42.44
11:15 ET	818	42.445
11:18 ET	5768	42.415
11:20 ET	100	42.415
11:22 ET	2010	42.42
11:26 ET	200	42.425
11:27 ET	400	42.425
11:29 ET	700	42.425
11:31 ET	500	42.425
11:33 ET	5197	42.425
11:36 ET	400	42.43
11:38 ET	500	42.425
11:40 ET	400	42.425
11:42 ET	4821	42.45
11:44 ET	400	42.4499
11:45 ET	2318	42.445
11:47 ET	318	42.445
11:49 ET	11048	42.445
11:51 ET	400	42.435
11:54 ET	800	42.435
11:56 ET	2900	42.435
11:58 ET	597	42.43
12:00 ET	400	42.43
12:02 ET	800	42.43
12:03 ET	1175	42.435
12:05 ET	7248	42.445
12:07 ET	218	42.435
12:09 ET	14385	42.495
12:12 ET	12004	42.47
12:14 ET	4695	42.46
12:16 ET	1218	42.45
12:18 ET	786	42.44
12:20 ET	600	42.43
12:21 ET	200	42.43
12:23 ET	200	42.43
12:25 ET	200	42.43
12:30 ET	100	42.43
12:32 ET	200	42.43
12:34 ET	200	42.43
12:36 ET	1600	42.44
12:38 ET	500	42.435
12:39 ET	100	42.43
12:41 ET	11191	42.46
12:43 ET	2146	42.45
12:45 ET	2100	42.46
12:48 ET	2648	42.455
12:50 ET	10953	42.475
12:52 ET	618	42.465
12:54 ET	2071	42.455
12:56 ET	500	42.45
12:57 ET	2509	42.455
12:59 ET	900	42.45
01:01 ET	4952	42.475
01:03 ET	3092	42.455
01:06 ET	100	42.455
01:08 ET	1290	42.455
01:10 ET	2954	42.465
01:12 ET	300	42.465
01:14 ET	200	42.465
01:15 ET	2100	42.45
01:17 ET	700	42.45
01:19 ET	1692	42.45
01:21 ET	1218	42.45
01:24 ET	300	42.45
01:26 ET	1410	42.45
01:28 ET	1536	42.45
01:30 ET	1800	42.45
01:32 ET	1200	42.445
01:33 ET	6022	42.45
01:35 ET	645	42.46
01:37 ET	400	42.45
01:39 ET	831	42.45
01:42 ET	600	42.45
01:44 ET	100	42.445
01:46 ET	2200	42.445
01:48 ET	2085	42.45
01:50 ET	799	42.445
01:51 ET	100	42.45
01:53 ET	500	42.445
01:55 ET	1200	42.445
01:57 ET	5815	42.455
02:00 ET	100	42.455
02:02 ET	1825	42.475
02:04 ET	1523	42.495
02:06 ET	200	42.495
02:08 ET	1432	42.48
02:09 ET	700	42.4725
02:11 ET	1500	42.4725
02:13 ET	818	42.475
02:15 ET	900	42.47
02:18 ET	900	42.47
02:20 ET	700	42.465
02:22 ET	1454	42.46
02:24 ET	1436	42.465
02:26 ET	3861	42.485
02:27 ET	2041	42.515
02:29 ET	1041	42.5
02:31 ET	1000	42.495
02:33 ET	900	42.4825
02:36 ET	3007	42.49
02:38 ET	700	42.5
02:40 ET	700	42.495
02:42 ET	706	42.49
02:44 ET	600	42.495
02:45 ET	1400	42.49
02:47 ET	1218	42.48
02:49 ET	2220	42.5
02:51 ET	618	42.495
02:54 ET	818	42.49
02:56 ET	700	42.48
02:58 ET	900	42.47
03:00 ET	963	42.46
03:02 ET	1400	42.47
03:03 ET	1200	42.45
03:05 ET	700	42.44
03:07 ET	9036	42.455
03:09 ET	2118	42.475
03:12 ET	2236	42.475
03:14 ET	2884	42.45
03:16 ET	300	42.44
03:18 ET	1397	42.43
03:20 ET	2000	42.425
03:21 ET	1000	42.43
03:23 ET	900	42.42
03:25 ET	200	42.425
03:27 ET	1200	42.42
03:30 ET	944	42.42
03:32 ET	1254	42.42
03:34 ET	2700	42.425
03:36 ET	1400	42.425
03:38 ET	2325	42.42
03:39 ET	1769	42.42
03:41 ET	11303	42.44
03:43 ET	2339	42.45
03:45 ET	1423	42.45
03:48 ET	1421	42.45
03:50 ET	4792	42.45
03:52 ET	11131	42.45
03:54 ET	14583	42.445
03:56 ET	13799	42.45
03:57 ET	12059	42.45
03:59 ET	32779	42.52

Data delayed at least 15 minutes.

Apr 30, 2024
- CEREVEL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Cerevel Therapeutics Holdings, Inc. (CERE) Buyout and Encourages Investors to Contact the Firm, from 8:00AM ET on Tuesday Apr 30, 2024 by Dow Jones
  8:00AM ET on Tuesday Apr 30, 2024 by Dow Jones
Apr 18, 2024
- DJ AbbVie's Bet on a Neuroscience Drug Maker Just Got Better -- Heard on the Street -- WSJ, from 12:17PM ET on Thursday Apr 18, 2024 by Dow Jones
  12:17PM ET on Thursday Apr 18, 2024 by Dow Jones
- Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease, from 6:30AM ET on Thursday Apr 18, 2024 by Dow Jones
  6:30AM ET on Thursday Apr 18, 2024 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesCERE Cerevel Therapeutics Holdings Inc	7.7B	-16.0x	---
United StatesPCVX Vaxcyte Inc	7.2B	-16.3x	---
United StatesVKTX Viking Therapeutics Inc	8.5B	-84.1x	---
United StatesRVMD Revolution Medicines Inc	6.9B	-10.4x	---
United StatesCYTK Cytokinetics Inc	6.8B	-11.9x	---
United StatesIBRX Immunitybio Inc	6.2B	-6.9x	---
As of 2024-05-06

Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder and Parkinson’s disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinson’s disease.

Contact Information

Headquarters: 222 Jacobs Street, Suite 200CAMBRIDGE, MA, United States 02141
Phone: 212-284-2300
Fax: 302-636-5454

Executives

Chairperson of the Board of Directors: N. Coles
President, Chief Executive Officer, Member of the Board: Ronald Renaud
Chief Financial Officer: Susan Altschuller
Chief Human Resources Officer: Kenneth Dipietro
Senior Vice President - Finance, Chief Accounting Officer: Mark Bodenrader

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$7.7B
Revenue (TTM)	$0.00
Shares Outstanding	181.9M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	1.47
EPS	$-2.66
Book Value	$3.71
P/E Ratio	-16.0x
Price/Sales (TTM)	---
Price/Cash Flow (TTM)	---
Operating Margin	---

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Cerevel Therapeutics Holdings Inc
NASDAQ:CEREUnited States

Search Criteria

Charts

Recent News

Apr 30, 2024

CEREVEL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Cerevel Therapeutics Holdings, Inc. (CERE) Buyout and Encourages Investors to Contact the Firm, from 8:00AM ET on Tuesday Apr 30, 2024 by Dow Jones

Apr 18, 2024

DJ AbbVie's Bet on a Neuroscience Drug Maker Just Got Better -- Heard on the Street -- WSJ, from 12:17PM ET on Thursday Apr 18, 2024 by Dow Jones

Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease, from 6:30AM ET on Thursday Apr 18, 2024 by Dow Jones

Biotechnology Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar